HEALTH & WELLNESS

ICMR seeks private partners to jointly develop and commercialize new typhoid and paratyphoid vaccines through Expression of Interest.

By Aniket Chakraborty

Feb 19, 2025

Arrow
Arrow

Research foundation laid at ICMR-NIRBI Kolkata, where scientists discovered potential vaccine development from pathogen outer membrane structures.

2

Arrow

Selected companies must pay 2% royalty on net sales according to ICMR's Technology Development Collaboration guidelines.

3

Arrow

Three key pathogens targeted: Salmonella Typhi, Salmonella Paratyphi, and Salmonella Typhimurium.

4

Arrow

ICMR promises expert guidance and technical support throughout all phases of vaccine production.

5

Arrow

Companies will be evaluated based on their R&D plans, facilities, and capabilities before partnership.

6

Arrow

India recorded highest global typhoid cases in 2021 - approximately 1 crore cases, per CMC Vellore and ICMR study.

7

Arrow

Partners will handle both validation of vaccine technology and commercialization aspects.

8

Arrow

India currently has a WHO-approved indigenous Vi-TT conjugate vaccine for typhoid.

9

The initiative aims to reduce India's typhoid burden through improved treatment options.

10